Takeda Pharmaceuticals: Global Homepage
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Takeda Pharmaceutical Company - Wikipedia
The Takeda Pharmaceutical Company Limited[1] (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company.
Takeda in the U.S - Takeda Mission
Mar 31, 2024 · Employee-led U.S. Takeda Resource Groups fostering an equitable and inclusive work environment. Additionally, Takeda has earned multiple workplace awards for several consecutive …
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
1 day ago · Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials, giving the Japanese pharma confidence to move toward a 2026 approval filing in …
Takeda to invest $30B in US operations over the next five years
May 9, 2025 · Japanese drugmaker Takeda plans to invest $30 billion in its U.S. operations over the next five years, according to CEO Christophe Weber, who made the announcement Thursday during …
Takeda’s AI-Developed Psoriasis Pill Succeeds in Clinical Trials
1 day ago · Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition ...
Takeda Pharmaceutical Company (TAK) Company Profile & Description
Dec 9, 2025 · Company profile for Takeda Pharmaceutical Company Limited (TAK) stock, with a description, list of executives, contact details and other key facts.
Takeda Pharmaceutical (TAK) Stock Price, News & Analysis
3 days ago · Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, …
Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis ...
2 days ago · Takeda said more than half of plaque psoriasis patients treated with zasocitinib achieved clear or almost clear skin in two Phase 3 studies. Regulatory submissions for the TYK2 inhibitor are ...
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
2 days ago · The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.